Dear Colleagues,

Tuberculosis (TB) remains a worldwide health problem in spite of availability of drugs to cure TB as of a few decades ago. Some of the global issues in fighting TB are lack of appropriate diagnostic tools in high incidence countries, increasing incidence of drug-resistant TB due to misusing anti-TB medications, and lack of appropriate Direct Observed Therapy (DOT). The laboratory is an essential part of diagnosis, which should be able to perform mycobacterial culture and molecular methods to differentiate nontuberculous mycobacteria (NTM) from Mycobacterium tuberculosis.

The problem of drug resistant TB is growing worldwide. It has significant impact on patients and their family, and public health systems. To combat this relatively new threat, improving TB observed therapy methods, early detection of high risk groups of drug-resistant TB and enhancement of national TB programs with prevention strategies and treatment protocols are considered crucial.

The primary goal of this Special Issue is to build a platform to exchange experience, knowledge between epidemiologists, clinician-scientists, laboratory-scientists, and all related health professionals.

We are interested in patient-oriented and biologic-centered papers with solid clinical data that are applicable in the field of TB.

Topics that will be considered for this Special Issue include, but are not limited to:

• Current situation of drug-resistant TB in national and international levels
• New diagnostic tools, particularly point of care methods
• Frequency of NTM among TB subjects and its impact on TB outcome
• Tele-medicine and TB
• Potential role of biologic agents in TB treatment
• TB vaccine

Dr. Mehdi Mirsaeidi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Tuberculosis
• Diagnosis
• Drug-resistance
• Direct Observed Therapy
• Nontuberculous mycobacteria
• Mycobacterium tuberculosis
• Prevention and treatment
• TB vaccine